Spots Global Cancer Trial Database for ceritinib
Every month we try and update this database with for ceritinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer | NCT02227940 | Advanced Malign... ALK Positive Metastatic Panc... Stage III Pancr... Stage IV Pancre... | Ceritinib Cisplatin Gemcitabine Hyd... Laboratory Biom... Paclitaxel Albu... Pharmacological... | 18 Years - | Roswell Park Cancer Institute | |
| Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies | NCT02343679 | Hematologic Mal... | ceritinib | 18 Years - | Duke University | |
| Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | NCT05489887 | High-risk Neuro... | Naxitamab Ceritinib | 12 Months - 21 Years | Milton S. Hershey Medical Center | |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | NCT03611738 | Non-small Cell ... Lung Cancer Non-small Cell ... Non-small Cell ... Stage IV Non-sm... EGFR Negative N... | Ceritinib Docetaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) | NCT02186821 | Tumors With Abe... | Ceritinib | 18 Years - | Novartis | |
| A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors | NCT03546894 | Anaplastic Lymp... Carcinoma Non-s... | Brigatinib Alectinib Ceritinib Lorlatinib Any FDA Approve... | 18 Years - | Takeda | |
| Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | NCT02587650 | ALK Fusion Prot... BRAF wt Allele Invasive Skin M... MET Fusion Gene... NRAS wt Allele NTRK1 Fusion Po... NTRK2 Fusion Po... NTRK3 Fusion Po... RET Fusion Posi... ROS1 Fusion Pos... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... | Capmatinib Ceritinib Entrectinib Laboratory Biom... Regorafenib | 18 Years - | University of California, San Francisco | |
| Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | NCT03737994 | Lung Non-Squamo... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Alectinib Brigatinib Carboplatin Ceritinib Cisplatin Crizotinib Ensartinib Lorlatinib Pemetrexed | 18 Years - | National Cancer Institute (NCI) | |
| Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | NCT02587650 | ALK Fusion Prot... BRAF wt Allele Invasive Skin M... MET Fusion Gene... NRAS wt Allele NTRK1 Fusion Po... NTRK2 Fusion Po... NTRK3 Fusion Po... RET Fusion Posi... ROS1 Fusion Pos... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... | Capmatinib Ceritinib Entrectinib Laboratory Biom... Regorafenib | 18 Years - | University of California, San Francisco | |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | NCT05834348 | Non-Small Cell ... | lorlatinib crizotinib brigatinib ceritinib alectinib atezolizumab bevacizumab paclitaxel carboplatin docetaxel erlotinib gefitinib afatinib dacomitinib osimertinib pembrolizumab nivolumab entrectinib | 18 Years - 100 Years | Pfizer | |
| Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | NCT02299505 | Non-Small Cell ... | ceritinib | 18 Years - | Novartis | |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | NCT01685138 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| Next Generation Personalized Neuroblastoma Therapy | NCT02780128 | Neuroblastoma Cancer | Biopsy Next Generation... Tumor Scans Bone marrow Tes... Physical Exam Eye Exam Labs Pregnancy Test Interviews ECG Echocardiogram Ribociclib Ceritinib | 1 Year - 21 Years | Children's Hospital of Philadelphia | |
| A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors | NCT03546894 | Anaplastic Lymp... Carcinoma Non-s... | Brigatinib Alectinib Ceritinib Lorlatinib Any FDA Approve... | 18 Years - | Takeda | |
| Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma | NCT02513667 | ALK-positive No... | Ceritinib Stereotactic ab... | 18 Years - | University of Texas Southwestern Medical Center | |
| A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors | NCT02422589 | ALK-positive Ad... | ceritinib warfarin midazolam | 18 Years - | Novartis | |
| Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | NCT02559778 | Neuroblastoma | Ceritinib dasatinib sorafenib vorinostat DFMO | - 22 Years | Milton S. Hershey Medical Center | |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | NCT03611738 | Non-small Cell ... Lung Cancer Non-small Cell ... Non-small Cell ... Stage IV Non-sm... EGFR Negative N... | Ceritinib Docetaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors | NCT02422589 | ALK-positive Ad... | ceritinib warfarin midazolam | 18 Years - | Novartis | |
| Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma | NCT02513667 | ALK-positive No... | Ceritinib Stereotactic ab... | 18 Years - | University of Texas Southwestern Medical Center | |
| Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | NCT02289144 | Metastatic Anap... Locally Advance... | Ceritinib | 18 Years - | University of Texas Southwestern Medical Center | |
| Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | NCT02289144 | Metastatic Anap... Locally Advance... | Ceritinib | 18 Years - | University of Texas Southwestern Medical Center | |
| LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | NCT01828112 | Non-Small Cell ... | Ceritinib pemetrexed docetaxel | 18 Years - | Novartis | |
| Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer | NCT02321501 | ALK Positive Locally Advance... Metastatic Mali... ROS1 Gene Rearr... Stage IIIB Lung... Stage IV Lung N... | Ceritinib Everolimus Laboratory Biom... Pharmacological... | 18 Years - | M.D. Anderson Cancer Center | |
| Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma | NCT02513667 | ALK-positive No... | Ceritinib Stereotactic ab... | 18 Years - | University of Texas Southwestern Medical Center | |
| LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer | NCT01828099 | Non-Small Cell ... | Ceritinib Pemetrexed Cisplatin Carboplatin | 18 Years - | Novartis | |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | NCT03611738 | Non-small Cell ... Lung Cancer Non-small Cell ... Non-small Cell ... Stage IV Non-sm... EGFR Negative N... | Ceritinib Docetaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | NCT05489887 | High-risk Neuro... | Naxitamab Ceritinib | 12 Months - 21 Years | Milton S. Hershey Medical Center | |
| Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | NCT02587650 | ALK Fusion Prot... BRAF wt Allele Invasive Skin M... MET Fusion Gene... NRAS wt Allele NTRK1 Fusion Po... NTRK2 Fusion Po... NTRK3 Fusion Po... RET Fusion Posi... ROS1 Fusion Pos... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... | Capmatinib Ceritinib Entrectinib Laboratory Biom... Regorafenib | 18 Years - | University of California, San Francisco | |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | NCT01685138 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | NCT01685138 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| Managed Access Programs for LDK378, Ceritinib | NCT05100134 | Anaplastic Lymp... Non-small Cell ... | ceritinib | 12 Years - | Novartis | |
| Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma | NCT02729961 | Anaplastic Larg... CD30-Positive N... Systemic Anapla... | Brentuximab Ved... Ceritinib Laboratory Biom... Pharmacological... | 12 Years - | University of Washington | |
| Next Generation Personalized Neuroblastoma Therapy | NCT02780128 | Neuroblastoma Cancer | Biopsy Next Generation... Tumor Scans Bone marrow Tes... Physical Exam Eye Exam Labs Pregnancy Test Interviews ECG Echocardiogram Ribociclib Ceritinib | 1 Year - 21 Years | Children's Hospital of Philadelphia | |
| Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | NCT02638909 | Colorectal Aden... Cholangiocarcin... Pancreatic Aden... Hepatocellular ... Gastric Adenoca... Esophageal Aden... | ceritinib | 18 Years - | Criterium, Inc. | |
| Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer | NCT02227940 | Advanced Malign... ALK Positive Metastatic Panc... Stage III Pancr... Stage IV Pancre... | Ceritinib Cisplatin Gemcitabine Hyd... Laboratory Biom... Paclitaxel Albu... Pharmacological... | 18 Years - | Roswell Park Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
